Home/Pipeline/STRO-003

STRO-003

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Sutro Biopharma

About Sutro Biopharma

Sutro Biopharma is advancing a differentiated ADC platform and pipeline with the goal of redefining cancer therapy. Its core XpressCF® technology enables the cell-free synthesis and site-specific conjugation of proteins, allowing for the creation of homogeneous ADCs with optimized properties. The company's strategy combines internal development of lead assets, like luveltamab tazevibulin, with strategic platform partnerships to validate its technology. Despite a challenging market valuation, Sutro's clinical progress and platform capabilities position it as a unique player in the competitive ADC landscape.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed